INS and cancer: Except for the signaling pathways related to its malignant origination (pathways in cancer, pathways in cancer, transcriptional misregulation in cancer, etc.), steatotic HepG2 cells were featured by dysregulation of metabolic pathways (hsa01100), insulin signaling pathway (hsa04910), and insulin resistance (hsa04931).